IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - ScienceDirect
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study - Iversen - Journal of the European Academy of
A cutback in Imiquimod cutaneous toxicity; comparative cutaneous toxicity analysis of Imiquimod nanotransethosomal gel with 5% marketed cream on the BALB/c mice | Scientific Reports
IJMS | Free Full-Text | Exploring the Links between Obesity and Psoriasis: A Comprehensive Review
Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin | Scientific Reports
JCM | Free Full-Text | Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan
Pasi Paruppu Ladoo | Moong Dal Laddu | Nei Urundai - Subbus Kitchen
SKYRIZI® Efficacy in Active Psoriatic Arthritis (PsA)
Clinical improvement of psoriasis with DMF treatment in a 73-year-old... | Download Scientific Diagram
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and di
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis | Nature Communications
Phnom Penh Athletics Club: March 2021
Pharmaceuticals | Free Full-Text | Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic
Baseline demographic and disease characteristics of the intent-to-treat... | Download Table
Moong dal sundal recipe, Pasi paruppu sundal - Jeyashri's Kitchen
Depression outcomes in psoriasis patients | Download Table
Biomedicines | Free Full-Text | Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
PASI-75 and PASI-90 responder rates at weeks 4, 12, 24, and 52.... | Download Scientific Diagram
SKYRIZI® vs COSENTYX® Efficacy Data - Plaque Psoriasis